

Novel vaccine vectors for HIV-1

Nature Reviews Microbiology

12, 765-771

DOI: [10.1038/nrmicro3360](https://doi.org/10.1038/nrmicro3360)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pediatric Infectious Diseases: Getting Research Evidence into Practice and Generation of New Evidence. <i>Frontiers in Pediatrics</i> , 2014, 2, 138.	1.9	1
2	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	30.5	340
4	New approaches to HIV vaccine development. <i>Current Opinion in Immunology</i> , 2015, 35, 39-47.	5.5	77
5	A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine. <i>Frontiers in Immunology</i> , 2015, 6, 124.	4.8	26
6	Perspectives for immunotherapy: which applications might achieve an HIV functional cure?. <i>Oncotarget</i> , 2016, 7, 38946-38958.	1.8	12
7	AIDS Vaccines. , 2016, , 401-422.		1
8	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). <i>PLoS ONE</i> , 2016, 11, e0166393.	2.5	14
9	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16068.	4.1	48
10	Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. <i>Scientific Reports</i> , 2016, 6, 36658.	3.3	11
11	Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 614-619.	3.8	20
12	New concepts in HIV-1 vaccine development. <i>Current Opinion in Immunology</i> , 2016, 41, 39-46.	5.5	77
13	Viral vectors as vaccine carriers. <i>Current Opinion in Virology</i> , 2016, 21, 1-8.	5.4	52
14	Biologics to Treat Substance Use Disorders. , 2016, , .		3
15	Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. <i>Journal of Infectious Diseases</i> , 2016, 214, 369-378.	4.0	77
16	HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. <i>Expert Review of Vaccines</i> , 2016, 15, 709-717.	4.4	7
17	Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant. <i>Molecular Pharmaceutics</i> , 2016, 13, 885-894.	4.6	28
18	New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. <i>Expert Review of Vaccines</i> , 2016, 15, 1015-1027.	4.4	9
19	Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders. , 2016, , 229-248.		1

#	ARTICLE	IF	CITATIONS
20	Modified Vaccinia Virus Ankara. <i>Advances in Virus Research</i> , 2017, 97, 187-243.	2.1	233
21	Progress in HIV vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1018-1030.	3.3	80
22	An Engineered Virus Library as a Resource for the Spectrum-wide Exploration of Virus and Vector Diversity. <i>Cell Reports</i> , 2017, 19, 1698-1709.	6.4	49
23	In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. <i>Vaccine</i> , 2017, 35, 2042-2051.	3.8	9
24	Herpesviruses and Their Host Cells: A Successful Liaison. <i>Trends in Microbiology</i> , 2017, 25, 229-241.	7.7	50
25	Evaluation of the efficacy of a therapeutic HIV vaccine by in vitro stimulation assay. <i>Cellular Immunology</i> , 2017, 313, 67-71.	3.0	0
26	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. <i>Vaccine</i> , 2017, 35, 1-9.	3.8	14
27	Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-“STING”-Type I IFN Pathway and AIM2 Sensor. <i>Journal of Immunology</i> , 2017, 199, 3293-3305.	0.8	33
29	Post-exposure immunization by capsid-modified AdC7 vector expressing <i>Pseudomonas aeruginosa</i> OprF clears <i>P. aeruginosa</i> respiratory infection. <i>Vaccine</i> , 2017, 35, 7174-7180.	3.8	10
30	The state of gene therapy research in Africa, its significance and implications for the future. <i>Gene Therapy</i> , 2017, 24, 581-589.	4.5	11
31	Cell and Gene Therapy for HIV Cure. <i>Current Topics in Microbiology and Immunology</i> , 2017, 417, 211-248.	1.1	23
32	Replication-Competent Viral Vectors for Vaccine Delivery. , 2017, , 25-63.		1
33	First Impressions-“the Potential of Altering Initial Host-Virus Interactions for Rational Design of Herpesvirus Vaccine Vectors. <i>Current Clinical Microbiology Reports</i> , 2018, 5, 55-65.	3.4	3
34	Single-cycle adenovirus vectors in the current vaccine landscape. <i>Expert Review of Vaccines</i> , 2018, 17, 1-11.	4.4	25
35	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	4.4	26
36	Development of a Stable MGAT1- CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2313.	4.8	2
38	Collusion between neutralizing antibodies and other immune factions in the destruction of adenoviral vectors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10201-10203.	7.1	3
39	Novel Vector Construction Based on Alternative Adenovirus Types via Homologous Recombination. <i>Human Gene Therapy Methods</i> , 2018, 29, 124-134.	2.1	17

#	ARTICLE	IF	CITATIONS
40	HIV. Lancet, The, 2018, 392, 685-697.	13.7	219
41	First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines. MSphere, 2018, 3, .	2.9	15
42	Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. PLoS ONE, 2018, 13, e0196370.	2.5	16
43	A Systematic Review: The Role of Resident Memory T Cells in Infectious Diseases and Their Relevance for Vaccine Development. Frontiers in Immunology, 2018, 9, 1574.	4.8	59
44	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
45	Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy. Journal of Biological Research, 2018, 25, 3.	2.1	5
46	Cytomegalovirus Vaccines. , 2018, , 228-240.e6.		0
47	Ebola Vaccines. , 2018, , 276-287.e5.		0
48	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
49	Production of HIV-1-based virus-like particles for vaccination: achievements and limits. Applied Microbiology and Biotechnology, 2019, 103, 7367-7384.	3.6	30
50	A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Science Translational Medicine, 2019, 11, .	12.4	80
51	Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine. Vaccine, 2019, 37, 6696-6706.	3.8	7
52	Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Vaccines, 2019, 7, 119.	4.4	5
53	Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens. Cells, 2019, 8, 507.	4.1	9
54	Defining Kinetic Properties of HIV-Specific CD8+ T-Cell Responses in Acute Infection. Microorganisms, 2019, 7, 69.	3.6	3
55	Lessons for general vaccinology research from attempts to develop an HIV vaccine. Vaccine, 2019, 37, 3400-3408.	3.8	13
56	State-of-the-art human adenovirus vectorology for therapeutic approaches. FEBS Letters, 2019, 593, 3609-3622.	2.8	55
57	Antigen processing and presentation in HIV infection. Molecular Immunology, 2019, 113, 67-74.	2.2	8

#	ARTICLE	IF	CITATIONS
58	Semi-quantification of antibody-dependent enhancement (ADE) in the uptake of Adenovirus serotype 5 into THP-1 cells. <i>Analytical Biochemistry</i> , 2020, 591, 113568.	2.4	2
59	RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines. <i>Scientific Reports</i> , 2020, 10, 14056.	3.3	4
60	Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	8
62	HIV mRNA Vaccinesâ€™Progress and Future Paths. <i>Vaccines</i> , 2021, 9, 134.	4.4	45
63	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	28.9	145
65	Oral Vaccination Approaches for Anti-SHIV Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 702705.	4.8	2
66	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. <i>Communications Biology</i> , 2021, 4, 713.	4.4	17
67	Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. <i>PLoS Pathogens</i> , 2021, 17, e1009278.	4.7	18
68	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. <i>Biomaterials</i> , 2021, 276, 121062.	11.4	12
69	Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination. <i>Journal of Virology</i> , 2021, 95, e0092521.	3.4	9
70	Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56. <i>Journal of General Virology</i> , 2018, 99, 135-147.	2.9	17
72	Utilizing a TLR5-Adjuvanted Cytomegalovirus as a Lentiviral Vaccine in the Nonhuman Primate Model for AIDS. <i>PLoS ONE</i> , 2016, 11, e0155629.	2.5	8
73	Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. <i>PLoS ONE</i> , 2017, 12, e0169247.	2.5	10
74	Construction and characterization of recombinant human adenovirus type 5 expressing foot-and-mouth disease virus capsid proteins of Indian vaccine strain, O/IND/R2/75. <i>Veterinary World</i> , 2015, 8, 147-155.	1.7	3
75	Use of lentiviral vectors in vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1571-1586.	4.4	16
76	NK Cells in HIV-1 Infection. , 2016, , 262-269.		0
77	Immunization Against Viral Diseases. , 0, , 351-370.		2
78	COVID-19 vaccination and HIV-1 acquisition â€œ Authorsâ€™ reply. <i>Lancet, The</i> , 2022, 399, e36.	13.7	0

#	ARTICLE	IF	CITATIONS
79	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of Virology, 2022, , e0003422.	3.4	7
80	Cytomegalovirus Vaccines. , 2023, , 258-274.e9.		0